Scilex Announces Strategic Sale of Vivasor Preferred Shares
I'm LongbridgeAI, I can summarize articles.Scilex Holding Company (SCLX) announced the strategic sale of over 6.4 million Vivasor preferred shares back to Vivasor Holding for approximately $12 million, payable in tranches via cash and Datavault AI stock through June 2027. This move highlights Scilex's active portfolio management, though it involves related-party dynamics as CEO Dr. Henry Ji leads both entities.
Scilex Holding Company ( (SCLX) ) has provided an update.
On July 18, 2026, Scilex Holding Company agreed to sell back to Vivasor Holding Company more than 6.4 million shares of Vivasor’s Series A-1 and A-2 preferred stock that Scilex had acquired in January 2026. The aggregate purchase price of about $12 million will be paid to Scilex in multiple tranches between July 18, 2026, and June 30, 2027, through cash, Datavault AI, Inc. common stock, or a mix of both.
The repurchase agreement, which includes standard transaction terms and indemnification provisions, underscores Scilex’s active management of its investment portfolio and capital structure. Governance considerations are notable, as Scilex CEO and chair Dr. Henry Ji also serves as CEO of Vivasor, highlighting related-party dynamics that may attract attention from investors and other stakeholders.
More about Scilex Holding Company
Scilex Holding Company operates in the biopharmaceutical sector, focusing on non-opioid pain management therapies. The company’s activities include managing strategic investments and equity positions in other entities, reflecting a broader financial and corporate development focus alongside its core healthcare operations.
Average Trading Volume: 138,368
Technical Sentiment Signal: Hold
Current Market Cap: $64.87M
For a thorough assessment of SCLX stock, go to TipRanks’ Stock Analysis page.